Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal  to Marapsin1
- Suitable for: WB, IP
- Reacts with: Human
Product nameAnti-Marapsin1 antibody 
DescriptionRabbit monoclonal  to Marapsin1
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Recombinant full length protein (His-tag) corresponding to Human Marapsin1 aa 1-290 (C terminal).
Database link: Q9BQR3
- WB: K562 whole cell lysate. IP: K562 whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferConstituent: 100% PBS
0.2 µm filtered solution
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab275632 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/2000.|
|IP||Use at an assay dependent concentration.
4-6 μL/mg of lysate
Tissue specificityExpressed predominantly in the pancreas.
Sequence similaritiesBelongs to the peptidase S1 family.
Contains 1 peptidase S1 domain.
- Information by UniProt
- CAPH2 antibody
- Channel activating protease 2 antibody
- Marapsin antibody
Marapsin1 was immunoprecipitated from 0.5 mg of K562 (human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate with 2 µL of ab275632 and 15 µL of 50% Protein G agarose. Western blot was performed from the immunoprecipitate using ab275632 at 1/200 dilution. Rabbit IgG (H+L) Dylight 800-labeled, was used as secondary antibody at 1/5000 dilution.
Lane 1: ab275632 IP in K562 lysate
Developed using the Odssey technique.
Anti-Marapsin1 antibody  (ab275632) at 1/500 dilution + K562 (human chronic myelogenous leukemia lymphoblast cell line ) whole cell lysate at 30 µg
Goat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution
Performed under reducing conditions.
Developed using the Odyssey technique.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab275632 has not yet been referenced specifically in any publications.